Ambrilia initiates Phase I/II prostate cancer trial Ambrilia Biopharma has initiated a Phase I/II clinical development program of its proprietary, novel three-month formulation of goserelin, in hormone-sensitive prostate cancer patients.The study is designed to assess the hormonal efficacy,...
Prostate cancer drug hope Scientists have unveiled a new drug for prostate cancer which they say could help up to 80 per cent of patients with the aggressive and previously untreatable form of the disease.Prostate cancer is the most common cancer in men, with 35...
Prostate cancer drug gives hope to 'untreatable' patients Scientists have unveiled a new drug for prostate cancer which they say could help up to 80 per cent of patients with the aggressive and previously untreatable form of the disease.Prostate cancer is the most common cancer in men, with 35...
Ambrilia Initiates Phase I/II Clinical Program of its Novel Goserelin Formulation in Prostate Cancer Author : Ambrilia Biopharma Inc.Category : Press Release News Alerts by Email click here ) News | Home MONTREAL, QUEBEC -- 07/21/08 -- Ambrilia Biopharma Inc.
(TSX: AMB) today announced that it has initiated the Phase I/II clinical...
Ambrilia Initiates Phase I/II Clinical Program of its Novel Goserelin Formulation in Prostate Cancer Ambrilia Biopharma Inc.(TSX: AMB) today announced that it has initiated the Phase I/II clinical development program of its proprietary, novel 3-month formulation of goserelin, in hormone-sensitive prostate cancer patients.
'We announced...
Ambrilia Initiates Phase I/II Clinical Program of its Novel Goserelin Formulation in Prostate Cancer Ambrilia Biopharma Inc.(TSX: AMB) today announced that it has initiated the Phase I/II clinical development program of its proprietary, novel 3-month formulation of goserelin, in hormone-sensitive prostate cancer patients.
'We announced...
Ambrilia Initiates Phase I/II Clinical Program of its Novel Goserelin Formulation in Prostate Cancer -- Ambrilia Biopharma Inc.(Toronto:AMB.TO - News) today announced that it has initiated the Phase I/II clinical development program of its proprietary, novel 3-month formulation of goserelin, in hormone-sensitive prostate cancer patients....
Ambrilia Initiates Phase I/II Clinical Program of its Novel Goserelin Formulation in Prostate Cancer - Ambrilia Biopharma Inc.(TSX:AMB) today announced that it has initiated the Phase I/II clinical development program of its proprietary, novel 3-month formulation of goserelin, in hormone-sensitive prostate cancer patients.
'We...
Ambrilia Initiates Phase I/II Clinical Program of its Novel Goserelin Formulation in Prostate Cancer - Ambrilia Biopharma Inc.(TSX:AMB - News) today announced that it has initiated the Phase I/II clinical development program of its proprietary, novel 3-month formulation of goserelin, in hormone-sensitive prostate cancer patients.
'We...
Prostate Cancer Therapy May Not Help Hormone Therapy Doesn't Increase Survival in Older Men With Early Prostate Cancer July 8, 2008 One in four elderly U.S.men with early prostate cancer undergoes hormone therapy but it's more likely to harm than help.
Surgery to remove...
Prostate Cancer Therapy May Not Help -- One in four elderly U.S.men with early prostate cancer undergoes hormone therapy -- but it's more likely to harm than help.
Surgery to remove the prostate -- radical prostatectomy -- is too risky for most men in their 70s and 80s.
Schweizerhall: Swissmedic Approved Goserelin Implant --- Swissmedic, the Swiss Agency for Therapeutic Products, has approved the goserelin implant (original product: Zoladex by AstraZeneca) developed by Novosis.The goserelin implant is the first sterile implant from a series of...
